Ategenos Achieves Groundbreaking Patent for SmartPatch Combatting Medication Non-Adherence Costing $1T+

Ategenos Secures Foundational U.S. Patent for SmartPatch

In a significant advancement in the healthcare sector, Ategenos, a pioneering pharmatech company, has successfully obtained a foundational U.S. patent for its innovative SmartPatch platform. This platform is designed to tackle the staggering $1 trillion global problem of medication non-adherence, which leads to preventable healthcare costs and adverse patient outcomes.

The patent numbers, U.S. Patent No. 12,329,861, protect the core architecture of the wearable SmartPatch™. Combining transdermal drug delivery with low-cost, disposable electronics, this device allows for real-time monitoring and efficient caregiver interventions when patients miss medication doses.

"Medication non-adherence is one of healthcare's most expensive and preventable failures," says Don DeGolyer, CEO of Ategenos. His comments reflect the urgency in addressing an issue that directly impacts patients' health and healthcare systems worldwide.

The innovative features of the SmartPatch include its ability to wirelessly notify caregivers about an at-risk patient’s missed doses, thereby allowing for timely interventions that could stave off complications such as emergency room visits or hospital admissions. The technology harnesses the power of real-world evidence, bridging the gap between drug delivery, digital health, and analytics.

Ategenos's mission extends beyond merely addressing medication adherence; it also seeks to enhance the daily stability and health of patients managing chronic conditions. By preventing missed doses before they escalate into more serious health issues, the SmartPatch not only safeguards patient well-being but also alleviates stress for caregivers.

In an era where healthcare costs are climbing, Ategenos’s SmartPatch presents a scalable solution designed to improve life quality for both patients and caregivers while seeking to mitigate the broader economic implications of medication non-adherence.

As the healthcare landscape continues to evolve, the intellectual property protected by this patent solidifies Ategenos’s position as a leader in developing pivotal technologies that leverage better outcomes and lower costs. The company has several additional patent filings pending in the U.S., EU, and APAC regions, signaling further innovation to come.

Ategenos, headquartered in Massachusetts, is driven by a founding team that combines extensive experience in global pharmaceuticals with cutting-edge technological innovation from MIT. Together, they aim to reduce the health risks associated with missed doses and address the pressing issue of medication non-adherence that burdens today’s healthcare systems.

Ateganos’s SmartPatch is poised to redefine how medication adherence is approached by empowering caregivers and patients alike. Through this pioneering technology, they aim to make substantial strides toward resolving one of healthcare's most persistent challenges.